Boston Scientific Warns of Material Financial Hit After Global Cyberattack
The medical device giant expects to miss Q3 and full-year 2026 guidance after a breach disrupted global shipping and order processing.
Boston Scientific is unlikely to meet its net sales growth and adjusted earnings per share (EPS) guidance for the third quarter and full year 2026. The company issued the warning following a major cyberattack that crippled its global operations.
Detected on August 25, 2026, the attack caused severe disruptions to the company's ability to process orders and ship critical medical devices worldwide, including cardiac devices. The company stated the incident will have a material impact on financial results for the remainder of the year.
Financial Fallout
The scale of the disruption is significant for a company of Boston Scientific's size. In 2025, the medical device leader generated approximately $20 billion in revenue, and it reported $5.4 billion in net sales for the second quarter of 2026.
While the company has not provided a specific dollar amount for the loss, external analysts are already quantifying the damage. Vijay Kumar, an analyst at Evercore ISI, has modeled a potential hit to Q3 revenue of 600 to 700 basis points, representing a 6% to 7% decline for the quarter.
Compounding Pressures
This cybersecurity crisis arrives at a precarious time for the company's financial forecasting. In July 2026, Boston Scientific had already adjusted its 2026 EPS guidance due to shifts in clinical administration. The August attack adds a layer of operational instability to a volatile fiscal year, forcing the company to navigate both administrative headwinds and technical failures.
Industry Implications
Beyond the balance sheet, the breach underscores the acute vulnerability of critical medical supply chains. Because Boston Scientific provides life-saving devices to hospitals globally, operational downtime extends beyond financial loss to potential disruptions in patient care and hospital inventory management. The incident serves as a stark reminder that cybersecurity in the healthcare sector is a matter of patient safety as much as data protection.
Recovery Outlook
Boston Scientific has indicated it is on the road to recovery, but the full extent of the operational backlog remains a primary concern for investors. Market observers are now watching for updated guidance and a detailed accounting of the recovery timeline to determine if the company can claw back some of the lost Q3 momentum in the final quarter of the year.